- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Patent holdings for IPC class C07D 295/13
Total number of patents in this class: 501
10-year publication summary
|
28
|
42
|
33
|
38
|
32
|
31
|
43
|
44
|
37
|
29
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Acuitas Therapeutics Inc. | 113 |
21 |
| Massachusetts Institute of Technology | 10024 |
14 |
| The Regents of the University of California | 19859 |
11 |
| Dow Global Technologies LLC | 10385 |
8 |
| The Board of Trustees of the University of Illinois | 2685 |
8 |
| Modernatx, Inc. | 1261 |
8 |
| Beam Therapeutics Inc. | 235 |
8 |
| Centre National de La Recherche Scientifique | 10395 |
7 |
| The Trustees of the University of Pennsylvania | 4311 |
7 |
| The Salk Institute for Biological Studies | 445 |
6 |
| South China University of Technology | 1772 |
6 |
| Recurium IP Holdings, LLC | 134 |
6 |
| Albert Einstein College of Medicine, Inc. | 575 |
5 |
| PTC Therapeutics, Inc. | 483 |
5 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2839 |
5 |
| University College Cardiff Consultants Limited | 276 |
5 |
| The Procter & Gamble Company | 22043 |
4 |
| BASF SE | 20874 |
4 |
| Allergan, Inc. | 2361 |
4 |
| Arbutus Biopharma Corporation | 177 |
4 |
| Other owners | 355 |